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Mitogen-activated protein (MAP) kinases p42mdpk and p44mark are activated by dual tyrosine and threonine phosphorylation in vivo. Both MAPKs 
are phosphorylated and activated in vitro by an activator recently identified as a protein-tyrosine/threonine kinase. We have isolated a putative 
cDNA for a MAP kinase kinase (MAPKK) and determmed its structure [Proc. Natl. Acad. Sci. USA, in press]. The protein encoded by this cDNA 
shares sequence homology with two yeast protein kinases byrl and STE7. We now report that stimulation with serum of COS cells expressing this 
protein amplifies MAPK activator activity markedly. The increased activity co-migrates during chromatography with the expressed 45 kDa protein, 
recognized by an anti-STWlbyrl antibody, and is abrogated by treatment with phosphatase 2A. Thus, this cDNA encodes a functional MAPKK. 
The antiSTE7/byrl antibody also recognized a 46 kDa COS cell protein that was resolved from the expressed MAPKK by anion-exchange 
chromatography. This immunoreactive protein co-eluted with endogenous MAPKK activity, suggesting identification of the immunoreactive band 
as monkey MAPKK. 
1. INTRODUCTION 
MAP kinases comprise a family of protein serine/ 
threonine kinases which are activated by tyrosine and 
threonine phosphorylation in response to extracellular 
stimuli (reviewed in [l]). MAP kinases participate in 
protein kinase cascades thought to be important for 
transducing signals from these stimuli. In mammalian 
cells, three MAP kinases have been characterized, 
p42”“pk [2], ~44”“~~ [3]and ~55 MAP kinase [4]. ~42~“~~ 
and ~44”“~~ are activated in vitro by an activator dis- 
covered by Ahn et al. [5] and recently identified as a 
protein-tyrosine/threonine kinase, a ‘MAP kinase ki- 
nase’. The enzyme(s) responsible for activating ~55 
MAP kinase are unknown. 
protein sequence data we obtained for p42 MAP kinase 
kinase isolated from rabbit skeletal muscle [8]. To deter- 
mine whether the isolated cDNA encodes a functional 
MAPKK, we have expressed the encoded protein in 
COS cells and characterized its function. 
2. MATERIALS AND METHODS 
2.1. Materials 
Plasmid pCDM8 was purchased from Invitrogen (San Diego, CA). 
Goat anti-rabbit alkaline phosphatase was obtained from Promega 
(Madison, WI). Recombinant ~42”“‘~ was purified from E. Coli strain 
BL21(DE3)[pET-MK] as described previously [9]. The catalytic sub- 
umt of PP-2A and okadaic acid were purified to homogeneity from 
the sea sponge Halichondria’. Affinity purified Anti-STEll/byrl anti- 
body was a generous gift from Dr Steven L. Pelech (Kintech Biotech- 
nology Corp., BC, Canada). Dr. Pelech prepared the antibody with 
the following protocol. Peptide STE-VIII (FVGTSTYMSPERIC) was 
synthesized based upon a sequence (underlined) which is completely 
conserved in the catalytic subdomains VIII of Succharomyces cere- 
visiae STE7 and Schizossucharomyces pombe byrl [IO]. The peptide 
was coupled to KLH via a cysteine residue added to the C terminus 
and used to immunize New Zealand white rabbits. Subsequently, 
STE7I byrl antipeptide antibodies were purified from rabbit antisera 
over a STEIJ-VIII peptide-agarose affinity column. MAPKK cDNA 
(GenBank accession no. LO4485) was isolated and characterized as 
described [6]. 
We have isolated and sequenced a cDNA that en- 
codes a novel protein of 393 amino acids (43.5 kDa, 
predicted mass) with sequence similarity to the yeast 
protein kinases byrl and STE7 in the mating pathways 
of fission and budding yeast, respectively [6,7]. This 
cDNA was isolated from a rat kidney library using 
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2.2. Expression of rat kidney MAPKK cDNA in COS cells 
MAPKK cDNA was excised from plasmid pK28 [6] by digestion 
with Hind111 and Xbal and cloned into pCDM8 generating pCH1. 
Cos-1 cells were transfected with pCH1 or pCDM8 (control) by the 
DEAE-dextran method [l 11, or left untreated. Conditions for expres- 
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sion (48 h) and serum-deprivation (18 h) were essentially as described 
[12]. Cells were stimulated with serum for the indicated times, immedi- 
ately rinsed with 20 ml of chilled phosphate-buffered saline, and snap- 
frozen by floating the culture plates on an ethanol/dry ice bath. The 
plates were stored at - 20°C. 
2.3. Assays and chromatography 
Plates were thawed on ice in the presence of 1.0 ml of homogemza- 
tion buffer containing 50 mM j-glycerophosphate, 1.5 mM EGTA, 
1 mM dithiotbreitol, 1 mM PMSF and 1 mM benzamidine, 0.15 mM 
sodium orthovanada~. The cells were briefly sonicated (IO s) on ice 
and centrifuged (14 000 x g) for 15 min at 4°C. Portions of the super- 
natant (normalized for protein) were assayed for ability to activate 
p42”‘=@ asdescribed [9]. Extracts from pCDM8 and pCH1 transfected 
COS cells (k serum treatment) were characterized for MAPKK and 
MAPK by anion-exchange chromatography as described [9,13]. Con- 
ditions for protein phosphatase treatments were also as described 
previously [ 131. 
3. RESULTS AND DISCUSSION 
Transient expression of the protein was demonstrated 
by Western blotting using an antiSTE7fbyrl peptide 
antibody (Fig. I). The rationale for use of the antibody 
was based on functional and structural homologies be- 
tween MAPKK and STE;rfbyrl . STE7 and byrl have 
been identified as essential proteins in the signal 
transduction pathways for response to pheromones in 
5. cerevisiae and S. pombe, respectively [14,15]. STE7 
and byrl are thought to phosphorylate and activate 
yeast homologs of MAP kinase in each yeast [ 161. Com- 
parison with protein sequences in the data base revealed 
that the encoded protein was most similar to byrl (45% 
identity) [6]. The fourth -best FASTA score was ob- 
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Fig. 1. Western blotting with STE7/byrl antibody detects the ex- 
pressed protein encoded by pCH1 and an endogenous COS cell pro- 
tein. Single dishes of COS cells transfected with pCH1, pCDM8 (con- 
trol), or non- transfected cells were treated with (+) or without (-) 10% 
fetal calf serum for 5 min. The cells were washed with ice cold phos- 
phate-buffered saline and lysed in 1.0 ml homogenization buffer. Ex- 
tracts were prepared and corrected for protein. Samples (20~1, 20 pg 
total protein) from each condition shown were boiled in SDS sample 
buffer and characterized by SDS-PAGE and Western blotting with 
l,ug/ml of STE7lbyrl antibody. The antibody was detected with antr- 
rabbit alkaline phosphatase-links goat antibody. Each lane shown 
for pCH 1 and pCDM8 represent aseparate transfection of COS cells. 
tained for comparison to STE7 [6]. The anti-STE7lbyr1 
antibody was based on a sequence of twelve amino acids 
(FVGTSTYMSPERI) that are conserved in domain 
VIII of protein kinases STE7 and byrl. Ten of twelve 
amino acids of the corresponding sequence from the 
cDNA, FVGTRSYMSPERL, are also identical; non- 
identical residues (underlined) are separated by seven 
residues. FVGT and SYMSPERL are each of sufficient 
length to form an epitope. For these reasons, we evalu- 
ated expression of protein with this antibody. 
The antibody detected a 45 kDa band in COS cells 
transfected with pCH1 but not in control cells. The 
apparent mass of this band is nearly identical to the 
predicted molecular mass of 43.5 kDa. These data es- 
tablish that the antibody specifically recognizes the en- 
coded protein. The antibody also detected an additional 
band of 46 kDa. Recognition of both the endogenous 
46 kDa protein and the 45 kDa band appear to be 
specific because Western blotting with non-immune 
serum did not show cross reactivity with either band. 
Similarly, peptide competition studies with the STE7- 
VIII peptide, confirmed that the STE7/byrl antibody 
was specific for these proteins (data not shown). Thus 
the immunoreactive COS cell protein may be a related 
protein. 
To more fully characterize MAPKK activity in pCH 1 
and pCDM8 transfected cells, extract supernatants 
were fractionated by anion-exchange chromatography 
and assayed for MBP kinase activity in the presence and 
absence of recombinant p42mapk (Fig. 2). Fractionation 
of extracts from serum-treated pCH1 cells resolved a 
minor (fraction 5) and a major peak (fraction 7) of 
MAPKK activity (Fig. 2A). Neither of these activities 
were detectable in p~Hl-transfected COS cells that 
were not stimulated with serum, indicating that 
MAPKK protein expressed from pCH1, like en- 
dogenous COS cell MAPKK, was not constitutively 
active. Fractionation of extracts from serum treated 
pCDMX-transfected COS cells revealed a small activa- 
tion of endogenous COS cell MAPKK (Fig. 2B). No 
stimulation of MAPKK or MAPK was detected in col- 
umn fractions from non-serum treated pCDM8 cells. 
When column fractions were assayed for MBP kinase 
activity, two serum stimulated peaks were resolved 
eluting at 125 mM NaCl and 150 mM NaCl in both 
pCDM&or pCHl-transfected cells. These corre- 
sponded respectively to p42”“Pk and p44-pk, as deter- 
mined by cross reactivity with an antipeptide antibody 
raised to the amino acid sequence RRITVEEALAH- 
PYLEQYYDPTDE representing (residues 307-327) a 
conserved sequence in both MAPK isoforms [2] (data 
not shown). Interestingly, p44mapk appeared to be more 
significantly activated (4 to 5-fold) relative to p42mapk 
(2-fold) in pCH1 transfected cells (compare Fig. 2A 
with 2B). These results suggest that distinct cellular 
isoforms of MAPKK exist which show a s~cificifity 
towards either ~42”“~~ or p44”“Pk. 
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Fig. 2. Anion-exchange chromatography of pCH1 and pCDM8 trans- 
fected COS cell extracts. Extracts prepared from pCHI- (A) or 
pCDM8-transfected (B) COS cells treated with (closed symbols) or 
without serum (open symbols) for 5 mm were applied to a Waters 
AP-1 anion-exchange column (0.8 mm x 10 cm). The column was 
developed at a flow rate of 0.5 ml per minute with a 50 ml linear salt 
gradient (0 to 400 mM NaCl) in 50 mM p-glycerophosphate, pH 7.31 
4”C/O.15 mM sodium orthovanidate0.5 mM EGTA/I mM dithiothre- 
itol. Fractions were assayed for MBP kinase activity in the presence 
(0) and absence (A) of recombinant p42mapk as described in Methods. 
Only the first 30 fractions are shown; no significant activity was de- 
tected later in the profile. 
The data shown in Fig. 2 demonstrate that pCHl- 
transfected cells contain two resolvable peaks of 
MAPKK. The second peak of activity is derived from 
the MAPKK expressed from pCH1 because this peak 
appears only in pCHl-transfected cells. The first peak 
of activity is the endogenous COS cell MAPKK. Since 
two proteins in pCHl-transfected cells were im- 
munoreactive with antiSTE7/byrl antibody, the data 
suggest that the immunoreactive proteins (Fig. 1) corre- 
sponded to two forms of MAPKK. This was confirmed 
by Western blotting of column fractions from each of 
the conditions with the STE7/byrl antibody. Fig. 3 
shows that the major peak of MAPKK activity appear- 
ing in serum-stimulated pCH 1 -transfected cells (frac- 
tion 7, Fig. 2A) co-elutes with the 45kDa protein ex- 
pressed from pCH1 in Fig. 1. The peak of endogenous 
MAPKK activity in pCDM8-transfected cells co-elutes 
with the 46 kDa protein detected in both pCHl- and 
pCDM8transfected cells (Fig. 1). These data show that 
the 45 kDa band is derived from the rat kidney 
MAPKK cDNA. The data also demonstrate conclu- 
sively that pCH1 cells express a fully functional 
MAPKK which is utilized the same serum-stimulated 
pathways that bring about activation of endogenous 
MAPKK. Furthermore, the amplified activation of 
~42”~p~ and p44”“pk in pCH 1 -transfected cells suggests 
that the expressed MAPKK functions normally to acti- 
vate both endogenous COS cell MAPKs. 
To further investigate pCH1 MAPKK activation the 
most active fractions from anion-exchange were pooled 
and treated with purified protein phosphatases (Fig. 4). 
As with MAPKK isolated from other sources [17], 
pCH1 expressed MAPKK could be completely inac- 
tivated by PP-2A. The enzyme showed some susceptibil- 
ity to PP-1, but was insensitive to PTPase 1 b or CD45 
(data not shown). Furthermore treatment of pCH1 
COS cells with micromolar concentrations of okadaic 
acid resulted in a profound activation of the expressed 
rat kidney MAPKK and endogenous COS cell 
MAPKK*. This data indicates that pCH1 MAPKK 
was activated by serine/threonine phosphorylation in 
response to serum and that the enzyme showed the same 
susceptibility to dephosphorylation and inactivation by 
PP-2A as wild type MAPKK. 
The finding that the endogenous monkey MAPKK 
was separable from the expressed rat MAPKK from 
pCH1 and apparently recognized by the anti-STE7/byrl 
was unexpected. This may represent a species differ- 
ence. However, heterogeneity of MAPKK activity has 
been detected during anion-exchange chromatography 
at early steps of purification of MAPKK from rabbit 
skeletal muscle [S]. In addition, two SDS-PAGE bands 
containing MAPKK activity were purified from rabbit 
skeletal muscle [8] and A431 cells [18]. 
This heterogeneity could be explained by differences 
in phosphorylation or proteolytic cleavage of a single 
protein or alternatively, by distinct isoforms. Distinct 
isoforms could arise from distinct mRNAs. Northern 
analysis with a 1.6 kb fragment of MAPKK cDNA 
revealed two transcripts (2.7 and 1.7 kb) in adult rat 
tissues and an additional 2.3 kb transcript in neonatal 
tongue, each sufficiently large to enclose MAPKK. 
These mRNAs appear to be derived from a single gene. 
We do not know as yet whether these mRNAs encode 
* C.M.M. Haystead and T.A.J. Haystead, unpublished work. 
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Fig. 3. Western blotting of anion-exchange column fractions with STE7/byrl peptide antibody. Column fractions from pCH1 and pCDM8 serum 
stimulated COS cell extracts were probed for MAPKK with the STE7/byrl as in Fig. 1. 
distinct proteins. Additional studies, including charac- 
terization of additional MAPKK cDNAs, will be neces- 
sary to determine the numbers of MAPKKs and the 
inter-species variation between any forms identified. 
Recently, v-raf [19] and activated c-raf-1 [20] were 
60 
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shown to activate MAPKK in vitro. The data obtained 
suggest that c-raf-1 may be an activator of MAPKK in 
vivo, but the number and identity of intracellular 
MAPKK-kinase(s) remains to be established. The dem- 
onstration herein that the isolated cDNA encodes a 
functional MAPKK will greatly expand approaches 
available to enumerate and identify these enzyme(s). 
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